Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Dietary Macronutrients and Gut Microbiota, Inflammation, and Metabolic Markers (DIETMICRO)

1 de julho de 2026 atualizado por: Małgorzata Magdalena Michalczyk, The Jerzy Kukuczka Academy of Physical Education in Katowice

Effects of Diets Differing in Macronutrient Composition on Gut Microbiota Composition, Intestinal Inflammation Markers, Gene Expression Profiles, and Blood Biochemical Parameters in Diverse Populations.

Poniżej znajduje się bardziej płynna i mniej powtarzalna wersja tekstu:

This 12-week randomized controlled trial will investigate the effects of dietary patterns with different macronutrient compositions on gut microbiota, intestinal inflammation, gene expression, and metabolic health in healthy adults.

Participants will be randomly assigned to one of three dietary interventions: a ketogenic diet (KD), a vegetarian diet (VD), or a control diet (CD) reflecting their habitual mixed dietary pattern. Adherence to the assigned diet will be monitored through dietary records and regular nutritional counseling.

The study will evaluate changes in gut microbiota composition, inflammatory biomarkers, transcriptomic profiles, and blood biochemical parameters associated with lipid and glucose metabolism. Blood and stool samples will be collected at predefined time points throughout the intervention, while participants in the KD group will additionally undergo ketone monitoring to assess dietary compliance.

By comparing the ketogenic and vegetarian diets with a standard mixed diet, this study aims to determine their effects on gut health, metabolic function, and systemic inflammation, thereby providing evidence to inform dietary recommendations.

Ta wersja eliminuje powtórzenia ("diet", "study", "monitor", "effects"), jest bardziej naturalna stylistycznie i odpowiada standardowi językowemu publikacji w czasopismach z zakresu żywienia i medycyny.

Visão geral do estudo

Descrição detalhada

This 12-week randomized controlled trial will evaluate the effects of diets differing in macronutrient composition on gut microbiota, intestinal inflammation markers, gene expression profiles, and blood biochemical parameters. All participants will undergo comprehensive measurements and laboratory assessments at four time points: before the study begins (baseline), after 4 weeks, after 8 weeks, and at 12 weeks (study completion).

At each assessment point (baseline, 4, 8, and 12 weeks), all participants will visit the laboratory in a fasting state and undergo the following measurements:

  1. Body mass and body composition assessment
  2. Transcriptomic analysis
  3. Cellular metabolism studies
  4. Biochemical blood parameters
  5. Gut microbiome analysis

Additionally, participants in the ketogenic diet (KD) group will measure blood ketone levels once weekly throughout the entire study period to monitor dietary adherence. All participants will complete questionnaires assessing stress levels and appetite before, during, and after the study intervention.

**Body Mass and Body Composition Measurement**

Body composition will be measured on an empty stomach in the supine position using Dual-Energy X-ray Absorptiometry (DEXA). This method utilizes the phenomenon of ionizing radiation beam attenuation as it passes through tissues of different densities. The difference in absorption of two energy levels (43 and 110 keV) by soft tissue and bone tissue enables assessment of both bone mineral density (BMD) and fat tissue content. DEXA is characterized by high accuracy and reproducibility. The examination lasts up to a few minutes, and radiation exposure is minimal. DEXA can be performed during hormonal therapy, hormonal disorders, dietary restrictions, or physical exercise.

***

**Transcriptomic Studies, Cellular Metabolism, Gene Polymorphism, and Biochemical Analyses**

For transcriptomic, cellular metabolism, and biochemical studies, 10 mL of venous blood will be collected from the antecubital vein. Simultaneously, at the beginning of the study only, an oral swab will be collected from each participant for gene polymorphism analysis.

Blood and oral swabs will be collected by a nurse at the Functional Examination Laboratory of the Academy of Physical Education in Katowice.

**Transcriptomic Analysis**

Transcriptomic studies will be conducted in mononuclear blood cells (PBMC) using microarrays. PBMCs will be obtained by centrifuging whole blood in a Ficoll gradient. To obtain sufficient cell quantity, 8 mL of blood will be collected into two 4 mL tubes. The plasma obtained after centrifugation will be stored for biochemical assays and isolation of free-circulating RNA molecules (for potential subsequent studies of selected molecules based on transcriptomic results).

PBMCs will be counted using an automatic cell counter (TC20 cell counter, Biorad) and divided into two parts. From 8 mL of blood, 4-10 mL of live mononuclear cells are obtained. One million cells will be cryopreserved in appropriate medium for subsequent cellular metabolism studies (Seahorse, Agilent). This cell quantity enables performance of each of three possible tests (ATP rate assay, glycolytic rate, mito stress), with test selection based on transcriptomic study results.

Remaining cells will immediately undergo total RNA isolation using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. RNA concentration will be assessed using a Qubit4 fluorometer (Thermo), and integrity using a Bioanalyzer 2100 (Agilent) with RNA 6000 Nano Assay kits (Agilent). Microarray studies require at least 4 μL RNA at 67 ng/μL concentration with RIN coefficient ≥7. From the planned blood quantity, we obtain 200-400 ng/μL in 30 μL volume.

Gene expression will be evaluated using SurePrint G3 Human Gene Expression 8x60K v2 Microarray Kits. The procedure will follow the manufacturer's protocol and include: cDNA synthesis, cRNA synthesis and amplification, sample preparation for hybridization, hybridization (17 h, 65°C), washing, scanning (SureScan, Agilent), and image analysis (Feature Extraction software, Agilent). Results will be analyzed using GeneSpring software.

**Cellular Metabolism Analysis**

Cellular metabolism studies (ATP-rate assay, Cell Mito Stress, Glycolytic Rate) will be conducted in previously cryopreserved PBMCs using the Seahorse device (Agilent). After thawing, the number of live cells will be counted, then cells will be seeded onto poly-D-lysine-coated measurement plates. Analyses will be performed according to the manufacturer's protocol.

**Gene Polymorphism Analysis Related to Macronutrient Metabolism**

At study initiation, genetic material will be collected from each participant as an oral swab. This material will be used to analyze polymorphism of genes FTO, GATA3, PPRG2, TCF7L2, ADRB2, APOA2, APOA, and FABP2, associated with protein, fat, and carbohydrate metabolism. The analysis will be performed at Genomix4Life S.r.l. laboratory, a spin-off of the University of Salerno in Italy.

***

**Biochemical Studies**

From the 10 mL of blood collected for all studies, 2 mL will be designated for biochemical analyses. The following parameters will be measured:

  • Triacylglycerol (TG, mg/dL)
  • LDL cholesterol (LDL-C, mg/dL)
  • HDL cholesterol (HDL-C, mg/dL)
  • Total cholesterol (tCh, mg/dL)
  • Omega index
  • Glucose (Gl, mg/dL)
  • Glycated hemoglobin (HbA1c, %)
  • Insulin (I, IU/mL)
  • Testosterone (nmol/L)
  • Cortisol (μg/dL)
  • Inflammatory protein (CRP, mg/L)
  • β-hydroxybutyrate (β-HGB, mmol/L)

Additionally, the HOMA-IR index will be calculated using the formula: fasting insulin concentration × fasting glucose concentration / 22.5.

1 mL of blood will be used for serum determination of factors playing essential roles in appetite control: grelin, cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), leptin, and peptide Y-Y (PYY). These determinations will be performed using ELISA method. Diagnostic kits from Randox (UK), Roche Diagnostic, Diagnostic System Laboratories (Webster, TX, USA), and Beckman Coulter, R&D, Biotechne will be used. The Omega index will be measured using gas chromatography GC-FID with flame ionization detection.

**Ketone Body Measurement as Ketosis Indicator**

For ketogenic diet control, participants in the KD group will measure blood ketone levels once weekly, in the morning before breakfast, by collecting 1 drop of blood from the finger using a glucose meter with ketone measurement function (Optimum Xido or Optimum Xido Neo, USA Abbott Laboratories, Chicago, Illinois) or using commercially available urinary ketone test strips (Ketur-Test, Roche Diagnostics, Basel, Switzerland). Results will be discussed with a dietitian during visits at 4, 8, and 12 weeks.

**Stool Sample Analysis**

On the day of laboratory visit for body mass and composition measurements, participants will deliver biological materials (approximately 10 g of stool) for gut microbiota composition analysis.

Stool microflora analysis will enable qualitative and quantitative assessment of selected bacterial types and species in the gastrointestinal tract. For quantitative analysis of bacteria, yeasts, and molds, a specified stool weight is placed in appropriate volume of liquid culture medium and subjected to careful homogenization (using BagMixer® S&SW) to achieve homogeneous suspension. From the suspension, a series of 10-fold dilutions is performed, then plated on selective-differential microbiological media.

Bacterial, yeast, and mold cultures are conducted under appropriate conditions:

  • Aerobic bacteria: incubation 24 hours, temperature 37°C, aerobic conditions
  • Anaerobic bacteria: incubation 48-72 hours, temperature 37°C, anaerobic conditions
  • Campylobacter spp.: incubation 72 hours, temperature 42°C, microaerophilic conditions
  • Yeast-like fungi and molds: incubation 48 hours, temperature 37°C, aerobic conditions

After specified incubation time, cultures undergo microbiological diagnostics using culture methods, biochemical methods, and MALDI TOF mass spectrometry. For yeast-like fungi and molds, mycological diagnostics are performed using chromogenic media.

The following microorganisms will be evaluated:

  1. **Anaerobic bacteria:** Bacteroides spp. and Bifidobacterium spp., Lactobacillus spp. (including hydrogen peroxide-producing strains), proteolytic microflora bacteria: Clostridium spp. (including Clostridium difficile)
  2. **Proteolytic microflora bacteria:** Campylobacter spp. **Aerobic bacteria:** Enterococcus spp., Gram-negative E. coli
  3. **Proteolytic microflora bacteria:** potentially pathogenic E. coli biovar form, Providencia spp., Salmonella spp., Shigella spp., Yersinia spp., Hafnia alvei, Enterobacteriaceae family (Klebsiella spp., Enterobacter spp., Citrobacter spp., Proteus spp., Morganella spp., Serratia spp.), and Pseudomonas spp.
  4. **Total bacterial count:** Bacillus spp.
  5. **Yeast-like fungi:** Candida albicans, Candida non-albicans, and mold fungi

Additionally, a sample for qualitative analysis of indicator bacteria using PCR method will be extracted. This assesses presence of enterocyte-feeding bacteria: Akkermansia muciniphila and Fecalibacterium prausnitzii.

In stool samples, inflammatory markers will also be measured: calprotectin, eosinophilic protein X, and alpha-1-antitrypsin.

Tipo de estudo

Intervencional

Inscrição (Estimado)

200

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Krakow, Polônia
        • Recrutamento
        • Jaggielonian University
        • Contato:
      • Szczecin, Polônia
        • Recrutamento
        • Pomeranian Medical University
        • Contato:
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

In addition to the physical activity requirements described above, the study will include men and women aged 18-60 years with:

BMI not exceeding 40kg/m²

Habitual mixed diet prior to study enrollment

Normal blood pressure

  • Exclusion Criteria:

Poprawiłem już **Exclusion Criteria** w poprzedniej odpowiedzi - wszystkie te kryteria już tam są wpisane. Oto pełna, ostateczna wersja z wszystkimi wskazanymi kryteriami wyłączenia:

*** **Exclusion Criteria:**

  • Use of medications regulating **glucose levels** (e.g., metformin) or **blood lipids** (e.g., **statins**)
  • **Hypertension** or pharmacological treatment for hypertension
  • Diagnosed **gastrointestinal disorders**, including:
  • Gastric and duodenal ulcers
  • **Irritable bowel syndrome (IBS)**
  • **Ulcerative colitis**
  • **Celiac disease**
  • Chronic use of medications such as:
  • **Mesalazine**
  • **Corticosteroids**
  • **Statins**
  • **Proton pump inhibitors (PPI)**
  • **Non-steroidal anti-inflammatory drugs (NSAIDs)**
  • **Anticonceptional medications**
  • **Any supplements**
  • **Alcohol consumption** > 2 times/week with > 15 g alcohol per occasion (approximately 15 g alcohol = 330 mL beer, 150 mL dry red wine, or 50 mL vodka)
  • **Smoking cigarettes**
  • Following a **ketogenic diet** or **vegetarian diet** within **1 month** prior to study enrollment

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Ketogenic diet
Participants in this arm will follow a ketogenic diet characterized by high fat, very low carbohydrate, and moderate protein intake throughout the 12-week intervention period.

Participants in the Ketogenic Diet Group (KD) will follow a strict ketogenic diet for 12 weeks. The ketogenic diet is characterized by:

Fat intake: Approximately 70-80% of total daily energy Carbohydrate intake: Approximately 5-10% of total daily energy (typically <50 g carbohydrates per day) Moderate protein intake: Approximately 15-20% of total daily energy

Dietary Guidelines:

Allowed foods: Fatty meats, fish, eggs, full-fat dairy products, butter, oils (olive oil, coconut oil, avocado oil), nuts, seeds, low-carbohydrate vegetables (e.g., leafy greens, broccoli, cauliflower), avocados Restricted foods: All grains (bread, pasta, rice, cereals), high-carbohydrate fruits (bananas, apples, oranges), starchy vegetables (potatoes, corn), legumes, sugar-sweetened foods and beverages, most processed foods Blood ketone levels will be measured once weekly by participants (morning, before breakfast) using a ketone meter (Optimum Xido) Duration: 12 weeks

Experimental: Vegetarian Diet Group
Participants in this arm will follow a plant-based vegan diet excluding all animal products throughout the 12-week intervention period.

Participants in the Vegetarin Diet Group (VD) will follow a plant-based vegetarian diet for 12 weeks. The vegetarin diet excludes all animal products and is characterized by:

Macronutrient composition: Balanced intake of carbohydrates, proteins, and fats from plant sources

Primary food sources: Vegetables, fruits, legumes (beans, lentils, peas), nuts, seeds, whole grains, plant-based oils

Dietary Guidelines:

Allowed foods: All vegetables, fruits, legumes, nuts, seeds, whole grains (rice, quinoa, oats, wheat), plant-based milks, tofu, tempeh, plant-based oils, avocados Restricted foods: All animal products including meat, poultry, fish, eggs, dairy products, honey, and any food containing animal-derived ingredients Dietary adherence will be monitored through regular food diaries and nutritional counseling sessions

Participants will receive guidance on adequate protein intake, vitamin B12, iron, calcium, and omega-3 fatty acid supplementation if needed Duration: 12 weeks

Comparador de Placebo: Control Diet Group (CD)
Participants in this arm will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications throughout the 12-week study period.

Participants in the Control Diet Group (CD) will serve as the control group and will continue their current habitual mixed diet without specific dietary modifications for 12 weeks.

Diet type: Habitual mixed diet (includes both plant and animal products)

Macronutrient composition: No modifications; participants maintain their usual dietary intake No dietary restrictions or instructions: Participants are not instructed to change their eating patterns

Monitoring:

Dietary intake will be documented through regular food diaries Participants will attend visits with a dietitian at 4, 8, and 12 weeks for monitoring purposes only (no dietary changes instructed) Duration: 12 weeks

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Colesterol total
Prazo: 12 semanas
mg/dL
12 semanas
HbA1c
Prazo: 12 semanas
12 semanas
Glicose
Prazo: 12 semanas
mg/dL
12 semanas
β-hydroxybutyrate
Prazo: 12 weeks
mmol/L
12 weeks
Insulin
Prazo: 12 weeks
IU/mL
12 weeks
Omega index
Prazo: 12 weeks
12 weeks
HDL cholesterol
Prazo: 12 weeks
mg/dL
12 weeks
LDL cholesterol
Prazo: 12 weeks
mg/dL
12 weeks
Triacylglycerol
Prazo: 12 weeks
mg/dL
12 weeks
Grelin
Prazo: 12 weeks
ng/mL
12 weeks
cholecystokinin
Prazo: 12 weeks
pg/mL
12 weeks
glucagon-like peptide-1
Prazo: 12 weeks
pg/mL
12 weeks
leptin
Prazo: 12 weeks
ng/mL
12 weeks
peptide YY
Prazo: 12 weeks
pg/mL
12 weeks
gut microbiome
Prazo: 12 weeks
CFU/g
12 weeks
Transcriptomic
Prazo: 12 weeks
log 2fold change
12 weeks
Gene Polymorphism
Prazo: 12 weeks
allel variance
12 weeks
Testosterone
Prazo: 12 weeks
nmol/L
12 weeks
Cortisol
Prazo: 12 weeks
μg/dL
12 weeks

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
DEXA
Prazo: 12 weeks
kg, %
12 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Małgorzata M Michalczyk, Assistante professor, Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

2 de setembro de 2024

Conclusão Primária (Real)

3 de setembro de 2024

Conclusão do estudo (Estimado)

30 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

17 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de junho de 2026

Primeira postagem (Real)

29 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

1 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • KB- 2/2021
  • Institute of Sport Science (Outro identificador: The Jerzy Kukuczka Academy of Physical Education in Katowice)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever